Revenue of $217.6M in 2026Q3 reflects a sharp -18.7% year-over-year decline, while net margin compressed to 18.5% from 31.2% in the prior quarter, suggesting the recent profit cushion is narrowing faster than headline results imply.
Nutex Health, Inc. (NUTX) annual income statement — 13-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'11 | Dec'10 |
|---|
| Sales/Revenue | 796.53M | 875.26M | 479.95M | 247.65M | 219.29M | 331.53M | 274.03M | 97.06M | 1.37M | 23.17K | 0 | 0 | 2.55M | 1.27M |
| Revenue Growth % | -18.82% | 82.36% | 93.8% | 12.93% | -33.85% | 20.98% | 182.34% | 7000.03% | 5800.87% | - | - | -100% | 101.26% | - |
| Cost of Goods Sold | 415.86M | 430.98M | 283.69M | 212.87M | 203.87M | 152.25M | 116.42M | 40.17M | 508.16K | 564.37K | 473 | 662 | 1.53M | 783.17K |
| COGS % of Revenue | - | 49.24% | 59.11% | 85.96% | 92.97% | 45.92% | 42.49% | 41.38% | 37.17% | 2436.19% | - | - | 60.01% | 61.84% |
| Gross Profit | 380.67M | 444.28M | 196.26M | 34.77M | 15.42M | 179.28M | 157.61M | 56.89M | 858.83K | -541.2K | -473 | -662 | 1.02M | 483.19K |
| Gross Margin % | 47.79% | 50.76% | 40.89% | 14.04% | 7.03% | 54.08% | 57.51% | 58.62% | 62.83% | -2336.19% | - | - | 39.99% | 38.16% |
| Gross Profit Growth % | - | 126.37% | 464.39% | 125.49% | -91.4% | 13.75% | 177.03% | 6524.14% | 258.69% | - | 28.55% | -100.06% | 110.92% | - |
| Operating Expenses | 69.67M | 168.66M | 65.64M | 66.55M | 422.02M | 9.02M | 4.43M | 22.18M | 1.7M | 1.81M | 448.12K | 532.33K | 1.86M | 1.83M |
| OpEx % of Revenue | - | 19.27% | 13.68% | 26.87% | 192.44% | 2.72% | 1.62% | 22.85% | 124.3% | 7828.82% | - | - | 73.13% | 144.46% |
| Selling, General & Admin | 68.8M | 168.66M | 58.56M | 36.07M | 20M | 5.46M | 4.43M | 59.87M | 1.16M | 1.81M | 448.12K | 532.33K | 1.86M | 1.83M |
| SG&A % of Revenue | - | 19.27% | 12.2% | 14.56% | 9.12% | 1.65% | 1.62% | 61.68% | 85.13% | 7828.82% | - | - | 73.13% | 144.46% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 285.88K | 0 | 0 | 545.22K | 25.64K | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | 0.09% | - | - | 39.88% | 110.7% | - | - | - | - |
| Other Operating Expenses | -1000K | 0 | 7.08M | 30.48M | 402.02M | 3.27M | 0 | -37.69M | -9.76K | -25.64K | 0 | 0 | 0 | 0 |
| Operating Income | 311M | 275.63M | 130.62M | -31.77M | -406.6M | 170.26M | 153.17M | 34.71M | -840.4K | -2.35M | -448.6K | -532.99K | -844.58K | -1.35M |
| Operating Margin % | 39.04% | 31.49% | 27.22% | -12.83% | -185.41% | 51.36% | 55.9% | 35.76% | -61.48% | -10165% | - | - | -33.14% | -106.31% |
| Operating Income Growth % | - | 111.01% | 511.1% | 92.19% | -338.8% | 11.16% | 341.29% | 4230.27% | 64.31% | -424.93% | 15.83% | 36.89% | 37.26% | - |
| EBITDA | 332.62M | 296.15M | 149.59M | -14.18M | -393.47M | 177.93M | 159.07M | 37.19M | -839.88K | -1.82M | -448.13K | -532.33K | -844.58K | -1.35M |
| EBITDA Margin % | 41.76% | 33.84% | 31.17% | -5.73% | -179.42% | 53.67% | 58.05% | 38.32% | -61.44% | -7855.48% | - | - | -33.14% | -106.31% |
| EBITDA Growth % | -10.37% | 97.97% | 1154.79% | 96.4% | -321.14% | 11.85% | 327.75% | 4527.83% | 53.85% | -306.09% | 15.82% | 36.97% | 37.26% | - |
| D&A (Non-Cash Add-back) | 21.62M | 20.53M | 18.97M | 17.59M | 13.13M | 7.66M | 5.9M | 2.48M | 522 | 535.02K | 473 | 662 | 0 | 0 |
| EBIT | 311.32M | 267.01M | 129.68M | -32.17M | -407.16M | 175.69M | 152.17M | 35.62M | -840.33K | -5.64M | -448.48K | -532.98K | -815.44K | -1.34M |
| Net Interest Income | -19.19M | -22.23M | -19.93M | -16.32M | -12.49M | -6.2M | -6.43M | -3.53M | -109.73K | -367.35K | -2.46K | -3.14K | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 68 | 0 | 114 | 4 | 29.14K | 8.27K |
| Interest Expense | 19.19M | 22.23M | 19.93M | 16.32M | 12.49M | 6.2M | 6.43M | 3.53M | 109.8K | 367.35K | 2.58K | 3.15K | 0 | 0 |
| Other Income/Expense | -18.92M | -30.84M | -20.87M | -16.72M | -13.05M | -773.88K | -7.43M | -2.62M | -109.73K | -3.65M | -2.46K | -3.14K | 29.14K | 8.27K |
| Pretax Income | 292.08M | 244.78M | 109.75M | -48.49M | -419.65M | 169.49M | 145.74M | 32.09M | -950.13K | -6.01M | -451.06K | -536.13K | -815.44K | -1.34M |
| Pretax Margin % | 36.67% | 27.97% | 22.87% | -19.58% | -191.36% | 51.12% | 53.18% | 33.06% | -69.5% | -25932.29% | - | - | -31.99% | -105.65% |
| Income Tax | 59.05M | 64.42M | 14.48M | -5.07M | 13.09M | 965.73K | 181.34K | 0 | 0 | 0 | 0 | 0 | -432.05K | -1.5M |
| Effective Tax Rate % | 20.22% | 26.32% | 13.19% | 10.45% | -3.12% | 0.57% | 0.12% | 0% | 0% | 0% | 0% | 0% | 52.98% | 111.82% |
| Net Income | 164.71M | 70.79M | 52.18M | -45.79M | -424.78M | 132.59M | 105.97M | 20.92M | -2.81M | 582.06K | -7.43M | 83.81K | -383.39K | 158.14K |
| Net Margin % | 20.68% | 8.09% | 10.87% | -18.49% | -193.7% | 39.99% | 38.67% | 21.56% | -205.87% | 2512.57% | - | - | -15.04% | 12.49% |
| Net Income Growth % | 44.4% | 35.67% | 213.96% | 89.22% | -420.36% | 25.12% | 406.47% | 843.47% | -583.5% | 107.83% | -8968.07% | 121.86% | -342.44% | - |
| Net Income (Continuing) | 233.03M | 180.36M | 95.27M | -43.42M | -432.74M | 168.53M | 145.56M | 32.09M | -950.13K | -6.01M | -451.06K | -536.13K | -546.98K | -839.17K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6.98M | 0 | 0 | 0 |
| Minority Interest | 105.34M | 93.99M | 55.55M | 17.65M | 24.46M | 76.93M | 61.56M | 22.53M | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 23.39 | 10.48 | 9.71 | -10.39 | -100.36 | 33.55 | 24.69 | 4.88 | -0.02 | -0.07 | -3.60 | 0.04 | -0.32 | 0.13 |
| EPS Growth % | 23.04% | 7.93% | 193.46% | 89.65% | -399.14% | 35.88% | 405.94% | 24500% | 71.43% | 98.06% | -8967% | 112.69% | -346.15% | - |
| EPS (Basic) | - | 11.13 | 10.23 | -10.39 | -100.50 | 33.55 | 24.69 | 4.88 | -0.02 | -0.07 | -3.60 | 0.04 | -0.32 | 0.13 |
| Diluted Shares Outstanding | 7.04M | 6.76M | 5.1M | 4.41M | 4.23M | 3.95M | 4.29M | 4.14M | 7.18M | 4.18M | 2.07M | 2.07M | 1.2M | 1.2M |
| Basic Shares Outstanding | 6.85M | 6.36M | 5.1M | 4.41M | 4.23M | 3.95M | 4.29M | 4.14M | 7.18M | 4.18M | 2.07M | 2.07M | 1.2M | 1.2M |
| Dividend Payout Ratio | - | 104.93% | 12.34% | - | - | 108.86% | 55.72% | 90.34% | - | - | - | - | - | - |
Quick answers to the most common questions about buying NUTX stock.
For fiscal year 2025, Nutex Health, Inc. (NUTX) reported total revenue of $875.3M. This represents a 69016.0% increase compared to $1.3M in 2010.
Nutex Health, Inc. (NUTX) is profitable, generating $70.8M in net income for the fiscal year ending 2025 with a net profit margin of 8.1%.
Nutex Health, Inc. (NUTX) reported an operating income of $275.6M, resulting in an operating profit margin of 31.5%. This margin reflects the operational efficiency of the business before interest and taxes.
Nutex Health, Inc. (NUTX) generated $444.3M in gross profit for the year, representing a gross profit margin of 50.8%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Volatile Net Margin Compression
Metrics are mathematically derived from official filings.
Revenue Growth Decelerating From Peak Levels
Based on Nutex's reported quarterly figures, revenue reached $217.6M in 2026Q3 with year-over-year growth of -18.7%, following a run of mixed quarterly momentum that suggests the earlier surge is cooling rather than compounding.
The reported quarterly series shows revenue fluctuating between roughly $151.7M and $267.8M without a clean upward trend, which points to lumpy patient volumes or episodic revenue recognition rather than steady network expansion. The -18.7% year-over-year decline in the latest quarter, paired with a -13.6% decline in 2026Q2, warrants investigation into whether the earlier growth was partly driven by acquisitions or one-time collections. Investors should monitor whether revenue stabilizes near the $210M-$220M range that appears to be the recent baseline.
Gross Margin Volatility Undermines Pricing Stability
As reported in the quarterly financials, Nutex's gross margin swung from 30.4% in 2025Q4 to 67.0% in 2026Q2, a range that suggests the cost base or payer mix is not yet structurally anchored.
Such a wide gross margin band across adjacent quarters is more consistent with variable reimbursement timing, changes in payer mix, or cost classification shifts than with durable pricing power. The 46.7% latest-quarter gross margin sits well below the 67.0% peak, which may indicate that the higher-margin periods were not repeatable. Without disclosed detail on cost classification, the sustainability of the mid-range margin remains an open analytical question.
Operating Leverage Concentrated in Volume Peaks
According to reported figures, operating margin ranged from 13.8% to 57.8% across recent quarters, with SG&A remaining comparatively small at roughly $10M to $20M, implying that operating income is driven primarily by revenue and cost-of-service swings rather than overhead.
The low and relatively stable SG&A base indicates overhead efficiency, yet the large swings in operating income show that the fixed-cost structure of the facilities amplifies revenue variability. When revenue falls, operating income compresses sharply, as seen in the move from 57.8% to 35.4% operating margin. This pattern suggests high operating leverage that cuts both ways and warrants monitoring of facility utilization.
Wide Operating-to-Net Gap Raises Questions
Based on Nutex's reported figures, the 2026Q3 operating margin of 35.4% compares with a net margin of 18.5%, and a net margin of -7.3% in 2025Q2 against a 13.8% operating margin, a gap that appears driven by non-operating items.
The persistent difference between operating and net margins suggests material below-the-line charges such as interest, amortization, or other non-operating items, though the provided data does not itemize them. Stock-based compensation of $78.7M in 2025Q2 alongside a net loss is a notable data point that may indicate compensation-driven earnings distortion. Earnings quality therefore appears difficult to assess from headline figures alone and merits deeper review of the reconciliation between operating and net income.
Sustainability of the Recent Profit Window
The strongest challenge is that Nutex's 2026Q3 EPS of $5.71 follows a year-over-year decline of 26.4%, suggesting the recent profit cushion may be narrowing faster than the headline beat implies.
A bear case would emphasize that revenue has fallen 18.7% year over year while operating margin compressed from 48.7% to 35.4%, a combination that points to earnings power under pressure. The operating margin of 35.4% remains high relative to the 18.5% net margin, and a continued squeeze on reimbursement or a rise in labor costs could compress margins further from elevated levels. Investors should treat the single-quarter EPS beat with caution until revenue growth re-establishes a consistent direction.